Key takeaways:
- Urine sodium–guided supplementation did not significantly improve weight, length, or head circumference by 36 weeks’ PMA in infants born at 25 to 29 weeks’ gestation.
- Most infants in the study algorithm group exhibited low urine sodium levels, prompting higher sodium intake compared with standard care.
- Despite higher sodium and protein intake, overall somatic growth outcomes were similar between study groups.
- No increase in morbidity or adverse clinical outcomes was associated with sodium supplementation.
- Urine sodium monitoring may still be useful for individualized management in preterm infants with poor growth despite adequate caloric and protein intake.
Data published in Pediatrics Open Science has highlighted no significant improvement in weight gain among infants born 25- through 29-weeks’ gestation at 36 weeks postmenstrual age (PMA) from sodium (Na) supplementation guided by urine Na concentrations.1
A significant correlation has been identified between in-hospital growth and impaired neurodevelopment among infants, leading to strong concerns about sub-optimal extrauterine growth. Na intake has been highlighted as a major factor in supporting somatic growth.2
“Preterm infants are at risk for Na depletion due to large, underappreciated urine Na (UNa) losses coupled with the low Na content of human milk and infant formula,” wrote investigators.1
Determining Na effects
The randomized controlled trial was conducted to guide dietary Na supplementation alongside standard care (SC) to promote somatic growth among preterm infants. Participants included infants born from 25- through 29-weeks’ gestation with a birth weight of at least 500 grams admitted within 1 week after birth.
Patients with major congenital anomalies, structural genitourinary abnormalities, intestinal ostomies, or diabetes insipidus were excluded from the analysis. Participants were randomized to either a study algorithm (SA) or standard care (SC) group and stratified by gestational age at birth.
Standard infant nutrition, provided to all patients before randomization, included 2 to 3 mEq/kg/day of Na alongside parenteral nutrition. Those in the SA group underwent an initial UNameasurement at 14 to 17 days postpartum, followed by regular measurements every 2 weeks until 36-weeks PMA.
Na administration and size outcomes
Na was given to SC infants at the medical care team’s discretion. In the SA group, Na supplementation was provided to infants with UNa measurements below the level outlined in the algorithm, with an initial amount of 4 mEq/kg/d chosen.
Medical records were assessed for maternal and infant demographic variables, birth history, infant comorbidities, weights, and nutrition data. Differences in somatic growth, including weight, length, and head circumference, were reported as the primary outcome. These differences were reported as changes in Z-scores between 2- and 36-weeks PMA.